Effects of dexamethasone and Salvia miltiorrhizae on the small intestine and immune organs of rats with severe acute pancreatitis.
To observe the protecting effects and mechanisms of Dexamethasone and Salviae miltiorrhizae on intestinal mucosa and immune organs (spleen, thymus and lymph node) in rats with severe acute pancreatitis (SAP). The rats were randomly divided into sham-operated, model control, Dexamethasone treated group and Salviae miltiorrhizae treated group. At 3, 6 and 12 h after operation, the mortality rate, pathological changes of intestinal mucosa and immune organs as well as the contents of serum PAF, IL-1 beta and sIL-2R were observed, respectively. The mortality rate and the contents of PAF (at 3 and 6 h), IL-1 beta (at all time points) and sIL-2R (at 3 and 6 h) as well as the pathological scores of thymus (at all time points) and spleen (at 3 h) in Dexamethasone treated group were significantly lower than those in model control groups (P < 0.05). The contents of PAF (at 3 and 12 h), IL-1 beta (at 6 and 12 h) and sIL-2R (at 3 and 6 h) as well as the pathological scores of thymus (at all time points) and spleen (at 3 and 12 h) in Salviae miltiorrhizae treated group were markedly lower than those in model control groups (P < 0.05). Since both Dexamethasone and Salvia miltiorrhizae can reduce the contents of serum PAF, sIL-2R and IL-1 beta, mitigate the pathological changes in the small intestine, spleen and thymus and reduce the mortality rate of SAP rats, they show good therapeutic effects on SAP rats.
Xiping
Zhang
Z
Department of General Surgery, Hangzhou First People's Hospital, Hangzhou, 310006, Zhejiang Province, China.
Yan
Pan
P
Xinmei
Huang
H
Guanghua
Feng
F
Meili
Ma
M
Jie
Ni
N
Fangjie
Zhang
Z
D000208:Acute Disease; D000818:Animals; D003907:Dexamethasone / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D053583:Interleukin-1beta / Q000097:blood; D007413:Intestinal Mucosa / Q000187:drug effects / Q000473:pathology; D007421:Intestine, Small / Q000187:drug effects* / Q000473:pathology; D008221:Lymphoid Tissue / Q000187:drug effects* / Q000473:pathology; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D010195:Pancreatitis / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D028321:Plant Preparations / Q000627:therapeutic use*; D010972:Platelet Activating Factor / Q000032:analysis; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D015375:Receptors, Interleukin-2 / Q000097:blood; D015427:Reperfusion Injury / Q000517:prevention & control; D027561:Salvia miltiorrhiza; D012720:Severity of Illness Index
D053583:Interleukin-1beta; D028321:Plant Preparations; D010972:Platelet Activating Factor; D015375:Receptors, Interleukin-2; D003907:Dexamethasone